B. Riley Comments on Immunic’s Q1 Earnings (NASDAQ:IMUX)

Immunic, Inc. (NASDAQ:IMUX) – Investment analysts at B. Riley upped their Q1 2025 earnings estimates for shares of Immunic in a research note issued on Wednesday, April 16th. B. Riley analyst W. Wood now anticipates that the company will post earnings of ($0.26) per share for the quarter, up from their prior estimate of ($0.29). B. Riley currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for Immunic’s current full-year earnings is ($0.94) per share. B. Riley also issued estimates for Immunic’s Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.17) EPS, Q4 2025 earnings at ($0.19) EPS and FY2025 earnings at ($0.75) EPS.

A number of other brokerages also recently issued reports on IMUX. William Blair initiated coverage on Immunic in a report on Tuesday, March 25th. They set an “outperform” rating on the stock. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Immunic in a research note on Tuesday, April 15th. D. Boral Capital restated a “buy” rating and issued a $17.00 price objective on shares of Immunic in a report on Thursday, April 10th. Finally, StockNews.com cut shares of Immunic from a “hold” rating to a “sell” rating in a report on Thursday, March 20th. One research analyst has rated the stock with a sell rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, Immunic has an average rating of “Buy” and an average target price of $13.20.

Immunic Price Performance

Shares of IMUX stock opened at $0.98 on Friday. Immunic has a 1-year low of $0.83 and a 1-year high of $2.11. The stock has a market capitalization of $93.90 million, a PE ratio of -0.80 and a beta of 1.91. The business has a 50-day moving average of $1.08 and a 200 day moving average of $1.14.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in IMUX. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Immunic by 90.0% during the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 204,579 shares of the company’s stock worth $205,000 after buying an additional 96,894 shares during the period. Millennium Management LLC grew its position in Immunic by 480.6% in the 4th quarter. Millennium Management LLC now owns 579,683 shares of the company’s stock valued at $580,000 after acquiring an additional 479,846 shares during the last quarter. Focus Partners Wealth lifted its holdings in Immunic by 1.1% during the 4th quarter. Focus Partners Wealth now owns 2,168,353 shares of the company’s stock valued at $2,168,000 after buying an additional 23,610 shares in the last quarter. Bridgeway Capital Management LLC grew its stake in Immunic by 11.5% in the 4th quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company’s stock worth $215,000 after acquiring an additional 22,200 shares in the last quarter. Finally, 683 Capital Management LLC grew its stake in Immunic by 2.2% in the fourth quarter. 683 Capital Management LLC now owns 700,000 shares of the company’s stock worth $700,000 after purchasing an additional 15,349 shares in the last quarter. Institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.